IP Library Granted Patent US 9,763,877
Granted Patent B2
US 9,763,877 · App. 14/822,065 · Granted Sep 19, 2017

Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract

Inventors: Neil F. Duffy, Jr. (Brighton, MA); Andrew McGillicuddy (Hanover, MA)
Assignee: EndoCellutions, Inc.
A61K9/0053A61K9/0019A61K35/12A61K35/28A61K35/35A61K35/50A61K35/51C12N5/06C12N5/0607C12N5/0653C12N5/0663C12N5/0667Y10S514/866
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,763,877
App. No.
14/822,065
Granted
Sep 19, 2017
Kind
B2
Abstract

The anatomic and functional arrangement of the gastrointestinal tract suggests an important function of this organ is its ability to regulate the trafficking of metabolites as well as control the equilibrium between tolerance and immunity through gut-associated lymphoid tissue, the neuroendocrine network, and the intestinal epithelial barrier. Combining nucleated cells from various tissues and introducing them directly into the small intestine will have a positive effect on diabetes.

Claims (20)

1. A method to treat diabetes comprising:

implanting nucleated cells including stem cells from multiple source tissues directly into tissue of the duodenum to reset or repair the immune system or to reset or repair metabolite production in the duodenum, the nucleated cells being a heterogeneous population of cells and including cells from a bone marrow aspirate, a fat aspirate, cord blood, Wharton's Jelly, or afterbirth tissue.

2. The method according to claim 1 wherein the nucleated cells are implanted through an endoscopic procedure.

3. The method according to claim 1 wherein the nucleated cells are injected into the wall of the duodenum.

4. The method according to claim 1 wherein the nucleated cells include cells from a bone marrow aspirate.

5. The method according to claim 1 wherein the nucleated cells include cells from a fat aspirate.

6. The method according to claim 1 wherein the nucleated cells include cells from cord blood.

7. The method according to claim 1 wherein the nucleated cells include cells from Wharton's Jelly.

8. The method according to claim 1 wherein the nucleated cells are derived from autologous tissue.

9. The method according to claim 1 further comprising delivering a portion of the nucleated cells into the venous or arterial system.

10. The method according to claim 1 further comprising:

sourcing nucleated cells from a patient; and

preparing the nucleated cells using the nucleated cells sourced from the patient, wherein the sourcing, preparing and implanting are performed in one point-of-care procedure.

11. The method according to claim 1 wherein the nucleated cells are implanted into the tissue of the duodenum of a patient diagnosed with type-1 diabetes during the progression of the destruction of the islets of the patient's pancreas.

12. The method according to claim 1 wherein the nucleated cells include subpopulations of nucleated cells from respective source tissues.

13. The method according to claim 1 further comprising:

in one point-of-care procedure,

preparing a combination of nucleated cells from multiple source tissues, the nucleated cells being derived from autologous tissue; and

implanting the combination directly into tissue of the duodenum of a patient diagnosed with type-1 diabetes during the progression of the destruction of the islets of the patient's pancreas.

14. The method according to claim 1 where the nucleated cells are implanted through injections that move in a spiral pattern along the wall of the duodenum.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2015
From: MCGILLICUDDY, ANDREW
To: ENDOCELLUTIONS, INC.
Reel/Frame 036575/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2015
From: DUFFY, NEIL F.
To: ECW THERAPEUTICS, INC.
Reel/Frame 036575/0841 →
CHANGE OF NAME Recorded Sep 15, 2015
From: ECW THERAPEUTICS, INC.
To: ENDOCELLUTIONS, INC.
Reel/Frame 036618/0601 →
Continuity (3)
Continuation 12697537 · Feb 1, 2010
Provisional Application 61152417 · Feb 13, 2009
Related Publication 20160101047A1 · Apr 14, 2016